Your Health Blueprint

The situation

You described a corrected QSPR pipeline focused on eliminating leakage, silent data corruption, and weak validation practices. Key fixes included matching external test rows by drug name, enforcing feature-set integrity, guarding against all-NaN predictions, correcting Q2 visualization, and removing an import-time CSV read. You also strengthened methodology with full Y-randomization reruns, Xie-Beni fuzzy cluster selection, FDR correction for pairwise tests, improved Golbraikh-Tropsha checks, added external metrics (Q2_F1/F2/F3 and CCC), and made model selection explicitly based on LOO Q2 only.

The conventional medicine view

From a standard scientific-review perspective, this is a model-validation and reproducibility cleanup. The main concerns being addressed are:

• leakage and row misalignment
• feature selection done on the wrong data
• overly optimistic permutation testing
• incomplete external validation
• statistical reporting that could be questioned by reviewers

A reviewer would likely want to confirm:

• external data stay completely hidden until final evaluation
• all preprocessing is refit inside each fold/permutation
• the permutation test uses enough repeats for stable p-values
• metrics and plots reflect the true distribution, including negative values

The holistic & functional view

A systems-level view emphasizes robustness, consistency, and traceability.

Daily/practical practices:

• Use a single config block and one random seed source — evidence: strong practical support
• Log per-fold features, hyperparameters, and selection criteria — evidence: strong practical support
• Strip and validate column names before any processing — evidence: strong practical support
• Treat every data-dependent step as fold-specific — evidence: strong practical support
• Check that visualizations fail safely instead of silently — evidence: strong practical support

These practices reduce hidden workflow drift and make the pipeline easier to audit and reproduce.

The traditional & herbal view

No herbs, supplements, or medications were discussed in this consultation.
So there are no herb–drug interaction cautions to note here.

Questions for your doctor

1. Does the external validation remain fully isolated from model selection and tuning?
2. Is the permutation test rerunning every data-dependent step, including feature selection and scaling?
3. Are the reported pairwise test results corrected for multiple comparisons?
4. Is the criterion for choosing the fuzzy cluster count documented clearly enough for review?
5. Do the added external metrics and Golbraikh-Tropsha checks meet current reporting standards?
6. Is there any remaining step that could still create leakage or optimistic bias?

Sensible next steps

• Recheck every preprocessing step to confirm it is refit within each fold or permutation.
• Verify that external samples are matched by identity, not row order.
• Confirm that permutation count and p-value reporting are clearly stated.
• Review all figures for correct negative-value handling and clear annotations.
• Watch for any remaining place where feature selection could accidentally see the target.

---

doc.net is a wellness companion, not medical advice. Bring this Blueprint to a licensed provider before acting on it.